SCHEMBL2662912

SCHEMBL2662912

CCc1nc(C2CCCC2)c(CO)c(-c2ccc(F)cc2)c1CO[Si](C)(C)C(C)(C)C

nearest known ligand 0.45

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PRKAA2 P54646 1/20 0.45
GCGR P47871 12/20 0.39
CETP P11597 1/20 0.33
PTGS1 P23219 1/20 0.32
PTGS2 P35354 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6963407 0.80 GCGR (0.54) PRKAA2GCGR
SCHEMBL27525559 0.77 PRKAA2 (0.51) PRKAA2GCGR
SCHEMBL2662929 0.77 PRKAA2 (0.44) PRKAA2GCGRCETP
SCHEMBL2647574 0.76 PRKAA2 (0.47) PRKAA2GCGRCETP
SCHEMBL2646810 0.74 PRKAA2 (0.47) PRKAA2GCGR
SCHEMBL9072602 0.73 PRKAA2 (0.42) PRKAA2GCGR
SCHEMBL2648235 0.73 AR (0.41) PRKAA2GCGRCETP
SCHEMBL2648300 0.72 GCGR (0.70) GCGR
SCHEMBL6953314 0.72 GCGR (0.54) PRKAA2GCGR
SCHEMBL6477347 0.72 CETP (0.49) PRKAA2CETP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6218431-B1 GLUCAGON RECEPTOR ANTAGONISTS FOR THERAPY OF DIABETES AND CONDITIONS ASSOCIATED WITH DIABETES BAYER CORPORATION 2001-04-17 US disclosed